MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Down 0.9% – Should You Sell?

Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) dropped 0.9% on Wednesday. The company traded as low as $1.11 and last traded at $1.16. Approximately 236,234 shares were traded during mid-day trading, a decline of 68% from the average daily volume of 741,666 shares. The stock had previously closed at $1.17.

MAIA Biotechnology Price Performance

The firm has a market cap of $67.91 million, a PE ratio of -1.77 and a beta of 0.27. The stock’s fifty day moving average price is $1.24 and its 200-day moving average price is $1.46.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, sell-side analysts anticipate that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Ramiro Guerrero bought 78,239 shares of the stock in a transaction dated Thursday, August 27th. The shares were acquired at an average cost of $1.39 per share, for a total transaction of $108,752.21. Following the acquisition, the director directly owned 689,081 shares in the company, valued at approximately $957,822.59. This trade represents a 12.81% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Vlad Vitoc purchased 73,000 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was bought at an average cost of $1.37 per share, with a total value of $100,010.00. Following the acquisition, the chief executive officer owned 1,049,121 shares of the company’s stock, valued at approximately $1,437,295.77. The trade was a 7.48% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 258,078 shares of company stock worth $352,426 over the last three months. Corporate insiders own 19.81% of the company’s stock.

Hedge Funds Weigh In On MAIA Biotechnology

Institutional investors have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP purchased a new stake in MAIA Biotechnology in the 2nd quarter valued at $51,000. Cable Car Capital LP purchased a new position in shares of MAIA Biotechnology during the 2nd quarter worth $741,000. BlackRock Inc. purchased a new position in shares of MAIA Biotechnology during the 2nd quarter worth $580,000. Centric Wealth Management acquired a new position in shares of MAIA Biotechnology during the 2nd quarter valued at about $1,107,000. Finally, PVG Asset Management Corp acquired a new position in shares of MAIA Biotechnology during the 1st quarter valued at about $46,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company’s research is centered on treatments designed to address telomere biology, a process that plays an important role in the growth and survival of cancer cells.

MAIA’s lead investigational product is THIO, also known as 6-thio-2′-deoxyguanosine, a telomere-targeting agent intended to selectively affect cancer cells. The company has been evaluating THIO in combination with immune checkpoint inhibitors for patients with advanced or metastatic non-small cell lung cancer, including through its THIO-101 clinical program.

MAIA Biotechnology is headquartered in Chicago and is led by Chief Executive Officer Vlad Vitoc, M.D.